Insights
Perspectives on clinical vendor selection and the trials market.
Data-driven takes on the bottlenecks, costs, and decisions that shape how sponsors choose vendors � and why getting it wrong is expensive.
Data Management in Clinical Trials: Why It's the Silent Budget Killer
Data rework costs sponsors up to 20% of total trial spend. From poor edit checks to post-lock query resolution, five leak points that drain budgets and how to plug each one.
Cost AnalysisProtocol Amendments: The Hidden Cost Multiplier Nobody Budgets For
Fifty-seven percent of Phase 3 trials require at least one protocol amendment, each costing a median $535K and adding three months. Seventy-two percent are preventable. Here's how to amend-proof your trial before it starts.
Site StrategySite Feasibility Assessments: Why 40% of Sites Underperform
Most site feasibility questionnaires are filled with optimism, not evidence. Nearly half of sites fail to hit enrolment targets. Five structural fixes sponsors can implement before the first patient is randomised.
Contract StrategyHow to Negotiate a Clinical Trial Contract Without Getting Burned
Sixty percent of sponsor-CRO relationships falter in year one. The cause isn't incompetence � it's contract misalignment. Six negotiation mistakes that cost sponsors millions and how to avoid each one.
Outsourcing StrategyFSP vs Full-Service CRO: When Hybrid Models Win
Most sponsors default to full-service outsourcing. But hybrid FSP models consistently deliver 15�30% savings. Here's how to decide which functions to unbundle and how to transition without breaking your programme.
Cost AnalysisThe True Cost of Choosing the Wrong Vendor
The CRO that saved you 15% on the bid may end up costing you 300% in delays, staff turnover, and lost data. Six hidden costs every sponsor should understand before signing.
Sponsor GuideHow to Evaluate a Clinical CRO: A Sponsor's Checklist
A practical 12-point checklist covering therapeutic fit, enrolment data, team continuity, pricing clarity, and exit provisions � the evidence that separates vendors who deliver from those who just sell well.
Market AnalysisWhy Vendor Selection Is the Hidden Bottleneck in Clinical Trials
The global CRO market will double to $200B by 2034. Yet 85% of trials still fail to enrol on time and site selection remains the most under-optimised decision sponsors make.
Quality StrategyMonitoring Strategies That Actually Protect Trial Integrity
Sponsors spend 25�30% of trial budgets on monitoring, yet critical findings surface months late. Risk-based monitoring, centralised statistical surveillance, and sponsor oversight are the strategies that actually work.
Quality StrategyWhy Sponsor Oversight Is the Missing Link in Quality By Design
QbD frameworks look rigorous on paper. But when sponsors hand oversight to vendors and walk away, the system that was supposed to prevent quality failures becomes the reason they go undetected.